Biosimilars & Biologics 2017

DESCRIPTION

The BioTech Pharma Summit – Biosimilars & Biologics 2017 will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.

Over 100 delegates working in biosimilars and biologics, proteins, antibodies and peptides, representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will be joining the Global summit in Porto, reserve your seat now at the Biosimilars & Biologics 2017!

KEY PRACTICAL LEARNING POINTS

  • Biosimilars Interchangeability
  • Biosimilar Orphan Drugs: The Next Regulatory Challenge
  • The latest trends of the Biosimilars & Biologics
  • Prognosis for the Global Biologics market in an era of transformative new technologies
  • Innovative products and technologies in the global biologics market
  • Sustainable biotech innovation and the emergence of biosimilars
  • Obtaining patent protection while operating in an “anti-patent” climate From biosimilar approval to biogenerics in clinical practice
  • Biosimilars in emerging markets – regulatory and commercial considerations
  • Establishing “Finger-print Like” Biosimilarity – Critical Characterization Strategies for Biosimilar Assessment

WHO SHOULD ATTEND?

The BioTech Pharma Summit (EPM Group) are exclusive events designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions. Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:

  • Biologics/Biotechnology/ Biogenerics
  • Biopharmaceuticals
  • Business Development
  • Chief Scientific Officer
  • Clinical Immunology
  • Commercial Affairs
  • Drug and Safety Assessment
  • Drug Safety & Risk Management
  • Intellectual property
  • Legislation and Policy Advice
  • Manufacturing Market
  • Strategy Marketing & sales
  • New Product Development
  • Pharmacovigilance
  • Preclinical and Clinical Development
  • Pricing and Reimbursement
  • Health Economics
  • Principal Scientist
  • Process Control and Analytical Technologies
  • Quality Affairs/ Quality Control
  • Regulatory Affairs
  • Regulatory Compliance
  • Legal Affairs
  • R & D
Former Vice-President INFARMED (National Authority of Medicines and Health Products)
Medical Director at Norwegian Medicines Agency
Director at Challand Biosimilar Consulting Ltd.
Owner & Principal at BioPhama Law Group, PLLC
Vice President at PAREXEL
Dairine Dempsey
CEO & co-founder at Open Orphan DAC
Uwe Gudat
Head of Safety, Biosimilars at Fresenius Kabi SwissBioSim GmbH
Life Sciences Global Director, Biopharma Services Development at SGS
Vice President at Samsung Bioepsis
Head of Global Business Franchise Immunology & Dermatology (I&D) at Novartis Pharmaceuticals
Programme Coordinator and Research Associate at CASMI Translational Stem Cell Consortium
Vice President, Thought Leadership at QuintilesIMS
Head of the Drug Product Division at Celltrion’s Inc.
Vice President Life Sciences Europe at HighPoint Solutions
Associate Vice President, Product Development and Strategic Program Management at Intas Biopharmaceuticals
Transaction Director at AstraZeneca
President at Personalized Medicine Coalition (PMC)
Managing Partner at IP Asset Ventures Ltd.
Principal Scientific manager at Biocon

 

 

Event Details
Sponsors